Recently, our group published the results of the first patients with type 1 diabetes treated with autologous hematopoietic SCT (AHSCT). 1 AHSCT is an experimental procedure aiming to reverse autoimmune destruction of islet cells in type 1 diabetes mellitus. It was performed in 12-35-year-old patients, less than 6 weeks from diagnosis and positive anti-GAD antibodies. BM hematopoietic stem cells were mobilized with 2 g/m 2 CY plus 10 mg/kg/day granulocyte CSF, harvested, cryopreserved and reinfused after conditioning with 200 mg/kg CY plus 4.5 mg/kg rabbit anti-thymocyte globulin. Alkylating agents such as CY are usually associated with deleterious effects upon reproductive function 2 and infertility after treatment is a psychosocial burden, as most of the type 1 diabetic patients are young. However, disturbances in reproductive function other than the chronic complications including erectile dysfunction and retrograde ejaculation have received little attention in patients with diabetes. 3 We analyzed pituitarytesticular function and sperm characteristics of male patients with type 1 diabetes undergoing AHSCT to evaluate potential impairment of gonadal function before and after treatment.
The data of 13 patients with confirmed type 1 diabetes enrolled into the clinical trial for treatment with AHSCT at the BMT Unit of the School of Medicine of Ribeira˜o Preto, Brazil, were retrospectively analyzed. Samples were collected before AHSCT and at 12-month intervals. Semen samples were evaluated for seminal volume, sperm count and motility according to the World Health Organization Guidelines. Morphology of spermatozoa was quantified according to Kruger's criteria. 4, 5 Plasma follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were determined by immunofluorometric assays (Delfia 80/505, Turku, Finland), and plasma testosterone level was determined by RIA. Serum C-peptide levels were measured during a 2-h mixed-meal tolerance test by RIA using commercial kits (Diagnostic Systems Laboratories Inc., Webster, TX, USA). Glycated hemoglobin A 1C (HbA 1C ) was measured by low-pressure liquid chromatography. Data were analyzed by Kruskal-Wallis test. C-peptide levels were analyzed as area under the curve (AUC). Correlations were analyzed by Spearman correlation test. Statistical significance was set at Po0.05.
The median age at diagnosis was 16 years (range, 14-31 years) and the median disease duration before transplantation was 40 days (range, 25-56 days). No patients had a history of drug or alcohol abuse or a smoking habit and none had evidence of a varicocele. Clinical, hormonal and semen characteristics, before and after CY treatment and transplantation, are summarized in Table 1 . Body mass index did not change after treatment. HbA 1C and daily insulin dose were significantly lower and C-peptide levels were significantly higher after treatment compared with pre-treatment levels, indicating improvement in metabolic Table 1 Clinical, hormonal and semen characteristics of DM1 patients before and after CY administration and AHSCT control of the disease due to higher pancreatic insulin secretion. Pre-treatment plasma concentrations of LH and FSH were within the normal range in the 13 patients and only one patient had low plasma testosterone levels. One year after transplantation, mean FSH levels were significantly increased. Three patients had high plasma levels of LH (1 patient) and FSH (2 patients). Only one patient had low plasma testosterone levels. After 2 years of treatment LH, FSH and testosterone levels were similar to the pretreatment values. Of the initial 13 patients analyzed before treatment, 8 and 4 agreed to collect semen for analysis 1 and 2 years after treatment, respectively. No patients had normozoospermia before or after transplantation. A total of 4 patients had low seminal volume, 2 patients had low sperm count, 13 patients had low sperm motility and 11 patients had morphological abnormalities. After treatment, mean sperm concentration and motility were low, and sperm concentration decreased significantly compared with pre-treatment values. Two patients had low seminal volume and all of them had low sperm counts and low sperm motility. In patients with normally formed sperm, the count was initially low and decreased significantly after treatment. In addition, after treatment, the incidence of severe sperm damage (oligoasthenoteratozoospermia) increased from 15.4 to 50% of patients in comparison with pre-treatment sperm evaluation. Of note, one of the patients who declined to collect a semen sample 2 years after treatment had fathered a child 6 months earlier and another patient who provided a semen sample at 2 years fathered a child 3 years after the collection. There was a significant negative correlation between HbA 1C and seminal fluid volume before treatment (r ¼ À0.5536, P ¼ 0.0497). No other significant correlation was found between HbA 1C and C-peptide, hormonal and semen variables before highdose CY treatment and transplant. On the basis of our results, we conclude that testicular function is impaired in patients with type 1 diabetes with short disease duration and may be even more affected by the administration of CY and AHSCT in spite of the improved metabolic control and insulin secretion obtained, at least during the 2-year follow-up of this small group of patients. In agreement with most studies, pre-treatment LH and FSH levels were normal in all patients studied and no correlations were observed between metabolic variables and LH, FSH or testosterone, suggesting normal hypothalamic-pituitary-testicular secretion. 3 However, some investigators have described decreased testosterone levels, decreased pituitary response to GnRH and abnormal steroid feedback on hypothalamic-pituitary secretion. 6 In the present series, no patients had normozoospermia pre-transplantation, and the most frequent abnormalities were low sperm motility and morphological alterations. Most studies agree that diabetes is associated with disturbances in spermatogenesis. However, a large and diverse spectrum of abnormalities in all semen parameters including semen volume, sperm count, sperm motility and morphology has been reported. 6, 7 A recent study has reported accumulation of advanced glycation end products in the reproductive tract of diabetic men. 8 However, the relationship between disease pathogenesis and reproductive function in men has not been well investigated and needs to be clarified. Regarding recovery of testicular function, restoration of spermatogenesis has been reported in up to 80% of patients within 4 years of CY treatment whether or not associated with BMT. 9, 10 Longer follow-up of this group of patients will clarify whether or not diabetes is reversible, and the effects of CY on reproductive function.
